Lilly Plans Mirikizumab Filing For Crohn’s After Phase III Success

 
• By Joseph Haas

Mirikizumab, already under review at the FDA for ulcerative colitis, bests placebo on two primary endpoints in Crohn’s. Lilly hopes to beat AbbVie’s Skyrizi, already approved for Crohn's, to market in UC.

Lilly logo
Lilly intends to go head-to-head with AbbVie's Skyrizi in IBD

More from Clinical Trials

More from R&D